BTIG Reiterates Buy on Sionna Therapeutics, Maintains $58 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.8%

Neg 0% Neu 88.8% Pos 0%

BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $58 price target.

Comments

No comments yet. Be the first!